Q linea AB
Research Q linea AB (QLINEA) on Bullrun: market cap SEK 349.60M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerQLINEA
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryMedical Devices
- CurrencySEK
- Market capSEK 349.60M
- Financial periodQ2 2026
- RevenueSEK 1.50M
- Net income-SEK 29.94M
- Free cash flow-SEK 30.08M
- Gross margin169.8%
Valuation Snapshot
latest market cap is SEK 349.60M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 11.28M | -SEK 182.48M | n/a | 35.4% | n/a | SEK 258.11M | SEK 5.85M | SEK 338.00M |
| FY2024 | SEK 2.36M | -SEK 216.87M | -SEK 187.49M | -311.9% | -1.86 | SEK 25.66M | SEK 151.21M | -SEK 27.46M |
| FY2023 | SEK 4.44M | -SEK 229.37M | -SEK 236.86M | n/a | -3.48 | SEK 81.90M | n/a | SEK 189.64M |
| FY2022 | SEK 12.79M | -SEK 268.69M | -SEK 268.11M | 113.2% | -9.2 | SEK 72.88M | n/a | SEK 163.19M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-28 | SEK 349.60M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Q linea AB
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Q linea AB's market cap?
Q linea AB's market capitalization is SEK 349.60M.
What does Q linea AB do?
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert. The company also develops Podler, a portable blood culture technology.